NPS Pharmaceuticals Expands Executive Leadership Team to Support its U.S. and International Growth and Global Orphan-Drug Leadership

In Press Release by Cameron

NPS Pharma logo 

Paul Firuta named President, U.S. Commercial Operations and Eric Pauwels promoted to President, NPS Pharma International 

March 25, 2014

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced the appointment and promotion of two key executives to support the company’s vision of becoming the world’s premier orphan drug business.

Paul Firuta has joined NPS as president, U.S. commercial operations. Most recently, Mr. Firuta was vice president and general manager, Americas for ViroPharma, Inc. While at ViroPharma, Mr. Firuta led the U.S. launch of the orphan biologic product, Cinryze®, a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema, or HAE. Cinryze was launched in December 2008 and generated $97 million in first-year sales, making it one of the most successful orphan drug launches in the U.S. Prior to ViroPharma, Mr. Firuta held commercial leadership positions at OraPharma, Inc. and SmithKline Beecham Pharmaceuticals (GlaxoSmithKline).

To support NPS’ continued expansion into international markets, Eric Pauwels has been promoted to the new position of president, NPS Pharma International and will be responsible for all international commercial operations. Since joining NPS in September 2011, Mr. Pauwels has built a high-caliber commercial team and directed the successful U.S. launch of Gattex® (teduglutide [rDNA origin]) for injection for adult Short Bowel Syndrome, or SBS. Before joining NPS, Mr. Pauwels led the worldwide commercial functions for the Human Genetic Therapies (HGT) division of Shire plc.

“I am delighted that Paul Firuta will be leading our U.S. Commercial Operations and serve as the U.S. counterpart to Eric Pauwels who will now devote his skills and talents to building our international capabilities. The expansion of our leadership team and focus will help us accelerate our global growth strategy to build the world’s premier rare disease company,” said Francois Nader, MD, president and chief executive officer, NPS Pharmaceuticals. “Paul’s successful track record makes him the ideal executive to deliver continued success for Gattex® while preparing for the launch of Natpara®. And Eric’s extensive experience building international commercial teams, along with his deep global understanding of the orphan drug landscape, makes him ideally suited to run our international commercial operations.”

Additional information about NPS is available through its corporate website,